Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) A compound of [[the]] formula VI:



VI

wherein

A is C(=O)OR[1], or C(=O)NHSO$_2$R[2], ~~C(=O)NHR[3], or CR[4]R[4']~~ wherein;

R[1] is hydrogen, or C_1-C_6alkyl~~, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl~~;

R[2] is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl;

~~R[3] is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, OC_1-C_6alkyl, OC_0-C_3alkylcarbocyclyl, OC_0-C_3alkylheterocyclyl;~~

~~R[4] is halo, amino, or OH; or R[4] and R[4'] together are =O;~~

~~R[4'] is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl;~~

wherein R[2]~~, R[3], and R[4']~~ ~~are~~ is ~~each~~ optionally substituted ~~from~~ with 1 to 3 substituents independently selected from the group consisting of halo, oxo, nitrile, azido, nitro, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, $NH_2C(=O)$-, Y-NRaRb, ~~Y-O-Rb~~ Y-O-Rb, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-NHSO$_p$Rb, Y-S(=O)$_p$Rb, Y-S(=O)$_p$NRaRb, ~~Y-C(=O)ORb~~ Y-C(=O)ORb and Y-NRaC(=O)ORb;

Y is independently a bond or C_1-C_3alkylene;

Ra is independently H or C_1-C_3alkyl;

Rb is independently H, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl or C_0-C_3alkylheterocyclyl;

p is independently 1 or 2;

M is CR[7]R[7'] ~~or NRu~~;

~~Ru is H or C_1-C_3alkyl;~~

~~R^7 is C_1-C_6alkyl, C_0-C_3alkylC_3-C_7cycloalkyl, or C_2-C_6alkenyl, any of which is optionally substituted with 1-3 halo atoms, or an amino, -SH or C_0-C_3alkylcycloalkyl group; or~~

~~R^7 is J;~~

$R^{7'}$ ~~is H or~~ taken together with R^7 forms a C_3-C_6cycloalkyl ring ~~optionally~~ substituted with ~~$R^{7'a}$~~ ~~wherein;~~

~~$R^{7'a}$ is C_1-C_6alkyl, C_3-C_5cycloalkyl, C_2-C_6alkenyl any of which may be optionally substituted with halo; or $R^{7'a}$ is~~ J;

q' is 0 ~~or 1~~ and k is1 ~~to 3~~;

Rz is H, or together with the asterisked carbon forms an olefinic bond;

Rq is H or C_1-C_6alkyl;

W is [[–CH_2-]], -O- or ~~-OC(=O)H, -OC(=O)-~~, -S- [[, –NH-, -NRa, -$NHSO_2$-, -NHC(=O)NH- or –NHC(=O)-, -NHC(=S)NH- or a bond]];

R^8 is a ring system containing 1 or 2 saturated, partially saturated or unsaturated rings each of which has 4-7 ring atoms and each of which has 0 to 4 hetero atoms selected from S, O and N, the ring system being optionally spaced from W by a C_1-C_3alkyl group~~, or R^8 is C_1-C_6alkyl~~; any of which R8 groups can be optionally mono, di, or tri substituted with R^9, wherein

R^9 is independently selected from the group consisting of halo, oxo, nitrile, azido, nitro, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, $NH_2C(=O)$-, Y-NRaRb, Y-O-Rb, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-$NHSO_p$Rb, Y-$S(=O)_p$Rb, Y-$S(=O)_p$NRaRb, Y-C(=O)ORb and Y-NRaC(=O)ORb; wherein said carbocyclyl or heterocyclyl moiety is optionally substituted with R^{10}; wherein

R^{10} is C_1-C6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, amino, sulfonyl, (C_1-C_3 alkyl)sulfonyl, NO_2, OH, SH, halo, haloalkyl, carboxyl, amido;

~~Rx is H or C_1-C_5 alkyl; or Rx is J:~~

~~T is –CHR^{11}- or –NRd-, where Rd is H, C_1-C_3alkyl or Rd is J;~~

~~R^{11} is H or R^{11} is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, any of which can be substituted with 1 to 3 substituents independenly selected from the group consisting of halo, oxo, nitrile, azido, nitro, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, NH_2CO-, Y-NRaRb, Y-O-Rb, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-$NHSO_p$Rb, Y-$S(=O)_p$Rb, Y-$S(=O)_p$NRaRb, Y-C(=O)ORb, Y-NRaC(=O)ORb; or R^{11} is J;~~

J~~, if present,~~ is a single 3 to 10-membered saturated or partially unsaturated alkylene chain ~~extending~~ that extends from the R^7/$R^{7'}$ cycloalkyl ~~or from the carbon atom to which R^7 is attached~~ to ~~one of Rd, Rj, Rx, Ry or R^{11}~~ G ~~to form~~ and forms a macrocycle, which chain is optionally

interrupted by one to three heteroatoms independently selected from: -O-, -S- or –NR^{12}-, and wherein 0 to 3 carbon atoms in the chain are optionally substituted with R^{14}; wherein;

R^{12} is H, C_1-C_6 alkyl, C_3-C_6cycloalkyl, or COR^{13};

R^{13} is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl;

R^{14} is independently selected from H, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, hydroxyl, halo, amino, oxo, thio, or C_1-C_6 thioalkyl;

m is 0 ~~or 1~~; n is 0 ~~or 1~~;

~~U is O or is absent;~~

~~R^{15} is H, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, any of which can be substituted with 1 to 3 substituents independently selected from the group consisting of halo, oxo, nitrile, azido, nitro, C_1-C_6 alkyl, C_0-C_3alkylheterocyclyl, C_0-C_3alkylcarbocyclyl, $NH_2C(=O)$, Y-NRaRb, Y-O-Rb, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-NHSO$_p$Rb, Y-S(=O)$_p$Rb, Y-S(=O)$_p$NRaRb, Y-C(=O)ORb and Y-NRaC(=O)ORb;~~

G is ~~–O–~~, -NRy-, or -NRjNRj-;

Ry is ~~H, C_1-C_3 alkyl; or Ry is~~ J;

one Rj is H and the other Rj is ~~H or~~ J;

R^{16} is H; or R^{16} is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, NH_2CO-, Y-NRaRb, Y-O-Rb, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-NHSO$_p$Rb, Y-S(=O)$_p$Rb, Y-S(=O)$_p$NRaRb, Y-C(=O)ORb, Y-NRaC(=O)ORb; or a pharmaceutically acceptable salt or prodrug thereof.

2. (Canceled)

3. (Original) A compound according to claim 1, with the partial structure:



4. (Withdrawn) A compound according to claim 1, with the partial structure



5. (Withdrawn-currently amended) A compound according to claim 4, wherein Rq is C_1-C_3 alkyl, ~~preferably methyl~~.

6-8. (Canceled)

9. (Currently amended) A compound according to claim ~~7~~ 1, wherein R^{16} is H, C_1-C_6alkyl or C_3-C_6cycloalkyl.

10-23. (Cancelled)

24. (Currently amended) A compound according to claim 1, wherein W is ~~–S-, a bond or especially~~ –O-.

25. (Currently amended) A compound according to claim ~~23 or~~ 24 wherein R^8 is optionally substituted C_0-C_3alkylcarbocyclyl or optionally substituted C_o-C_3alkylheterocyclyl.

26. (Currently amended) A compound according to claim 25, wherein the C_0-C_3 alkyl moiety is methylene ~~or preferably a bond~~.

27. (Currently amended) A compound of formula VI: ~~according to claim 26~~



VI

wherein

A is $C(=O)NHSO_2R^2$, or $C(=O)OR^1$ wherein;

R^1 is H or C_1-C_6 alkyl;

R^2 is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl;

wherein R^2, is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, oxo, nitrile, azido, nitro, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, $NH_2C(=O)$-, Y-NRaRb, Y-O-Rb, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-$NHSO_p$Rb, Y-$S(=O)_p$Rb, Y-$S(=O)_p$NRaRb, Y-C(=O)ORb and Y-NRaC(=O)ORb;

Y is independently a bond or C_1-C_3alkylene;

Ra is independently H or C_1-C_3alkyl;

Rb is independently H, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl or C_0-C_3alkylheterocyclyl;

p is independently 1 or 2;

M is $CR^7R^{7'}$;

$R^{7'}$ taken together with R^7 forms a C_3-C_6cycloalkyl ring substituted with J;

q' is 0 and k is 1;

Rz is H or together with the asterisked carbon forms an olefinic bond;

Rq is H or C_1-C_6 alkyl;

W is -O-, or -S- ;

J is a single 3 to 10-membered saturated or partially unsaturated alkylene chain that extends from the R^7/$R^{7'}$ cycloalkyl to G and forms a macrocycle, which chain is optionally interrupted by one to three heteroatoms independently selected from: -O-, -S- or $-NR^{12}$-, and wherein 0 to 3 carbon atoms in the chain are optionally substituted with R^{14}; wherein;

R^{12} is H, C_1-C_6 alkyl, C_3-C_6cycloalkyl, or COR^{13};

R^{13} is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl;

R^{14} is independently selected from H, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, hydroxy, halo, amino, oxo, thio, or C_1-C_6 thioalkyl;

m is 0; n is 0;

G is -NRy- or -NRjNRj-;

Ry is J;

one Rj is H and the other Rj is H or J;

R^{16} is H; or R^{16} is C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, C_0-C_3alkylheterocyclyl, NH_2CO-, Y-NRaRb, Y-O-Rb, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb, Y-NHSO$_p$Rb, Y-S(=O)$_p$Rb, Y-S(=O)$_p$NRaRb, Y-C(=O)ORb, Y-NRaC(=O)ORb;

wherein R^8 is C_0-C_3alkylaryl, or C_0-C_3alkylheteroaryl, either of which is optionally mono, di, or tri substituted with R^9, wherein;

R^9 is C_1-C_6 alkyl, C_1-C_6alkoxy, NO_2, OH, halo, trifluoromethyl, amino or amido optionally mono- or di-substituted with C_1-C_6alkyl, carboxy, C_0-C_3alkylaryl, ~~C_0-C_3alkylheteroaryl~~ or C_0-C_3alkylheteroaryl, ~~carboxyl~~ the aryl or heteroaryl being optionally substituted with R^{10}; wherein

R^{10} is C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6aloxy, amino optionally mono- or di-substituted with C_1-C_6alkyl, C_1-C_3 alkyl amide, sufonylC_1-C_3alkyl, NO_2, OH, halo, trifluoromethyl, carboxyl, or heteroaryl.

28. (Original) A compound according to claim 27 wherein R^9 is C_1-C_6 alkyl, C_1-C_6alkoxy, amino, di-(C_1-C_3 alkyl)amino, C_1-C_3alkylamide, aryl or heteroaryl, the aryl or heteroaryl being optionally substituted with R^{10}; wherein

R^{10} is C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, amino, mono- or di-C_1-C_3 alkylamino, amido, C_1-C_3 alkylamide, halo, trifluoromethyl, or heteroaryl.

29. (Original) A compound according to claim 28, wherein, R^{10} is C_1-C_6alkyl, C_1-C_6alkoxy, amino optionally mono- or di-substituted with C_1-C_3 alkyl, amido, C_1-C_3-alkylamide, halo, or heteroaryl.

30. (Original) A compound according to claim 29 wherein R^{10} is methyl, ethyl, isopropyl, tert-butyl, methoxy, chloro, amino optionally mono- or di substituted with C_1-C_3 alkyl, amido, C_1-C_3alkylamide, or C_1-C_3alkyl thiazolyl.

31. (Original) A compound according to claim 26, wherein R^8 is 1-naphthylmethyl, 2-naphthylmethyl, benzyl, 1-naphthyl, 2-napthyl, or quinolinyl any of which is unsubstituted, mono, or disubstituted with R^9 as defined.

32. (Original) A compound according to claim 31 wherein R^8 is 1-naphthylmethyl, or quinolinyl any of which is unsubstituted, mono, or disubstituted with R^9 as defined.

33. (Original) A compound according to claim 32 wherein R^8 is:



wherein R^{9a} is C_1-C_6 alkyl; C_1-C_6alkoxy; thioC_1-C_3alkyl; amino optionally substituted with C_1-C_6alkyl; C_0-C_3alkylaryl; or C_0-C_3alkylheteroaryl, C_0-C_3alkylheterocyclyl, said aryl, heteroaryl or heterocycle being optionally substituted with R^{10} wherein

R^{10} is C_1-C_6alkyl, C_0-C_3alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, amino optionally mono- or di-substituted with C_1-C_6alkyl, amido, C_1-C_3alkyl amide; and

R^{9b} is C_1-C_6 alkyl, C_1-C_6-alkoxy, amino, di(C_1-C_3alkyl)amino, (C_1-C_3alkyl) amide, NO_2, OH, halo, trifluoromethyl, carboxyl.

34. (Original) A compound according to claim 33, wherein R^{9a} is aryl or heteroaryl, either of which is optionally substituted with R^{10} as defined.

35. (Currently amended) A compound according to 34, wherein R^{9a} is selected from the group ~~consisted~~ consisting of:







wherein R^{10} is H, C_1-C_6alkyl, or C_0-C_3alkylcycloalkyl, amino optionally mono- or di-substituted with C_1-C_6alkyl, amido, (C_1-C_3alkyl)amide.

36. (Withdrawn) A compound according to claim 34, wherein R^{9a} is optionally substituted phenyl, preferably phenyl substituted with C_1-C_6alkyl; C_1-C_6alkoxy; or halo.

37. (Withdrawn) A compound according to claim 33, wherein R^8 is:



wherein R^{10a} is H, C_1-C_6alkyl, C_0-C_3alkylcarbocyclyl, amino optionally mono- or di-substituted with C_1-C_6alkyl, amido, (C_1-C_3 alkyl)amide, heteroaryl or heterocyclyl; and R^{9b} is C_1-C_6 alkyl, C_1-C_6-alkoxy, amino, di(C_1-C_3 alkyl)amino, (C_1-C_3 alkyl)amide, NO_2, OH, halo, trifluoromethyl, or carboxyl.

38. (Original) A compound according to any claim 33, wherein R^{9b} is C_1-C_6-alkoxy, preferably methoxy.

39. (Currently amended) A compound according to claim 1, wherein ~~A is $C(=O)NHSO_2R^2$~~ R^2 is optionally substituted C_1-C_6 alkyl .

40. (Withdrawn-Currently amended) A compound according to claim 39, wherein R^2 is ~~optionally substituted C_1-C_6 alkyl, preferably~~ methyl.

41. (Currently amended) A compound according to claim [[39]] 1, wherein R^2 is optionally substituted C_3-C_7cycloalkyl~~, preferably cyclopropyl~~.

42. (Withdrawn-Currently amended) A compound according to claim [[39]] 1, wherein R^2 is optionally substituted C_0-C_6alkylaryl~~, preferably optionally substituted phenyl~~.

43. (Withdrawn-Currently amended) A compound according to claim 1, wherein A is $C(=O)OR^1$ wherein R^1 is H .

44. (Withdrawn-Currently amended) A compound according to claim [[43]] 1 wherein A is $C(=O)OR^1$, wherein R^1 is H or C_1-C_6 alkyl~~, preferably hydrogen, methyl, ethyl, or tert-butyl~~.

45. (Cancelled)

46. (Currently amended) A compound according to claim ~~2~~ 1, wherein R^7 and $R^{7'}$ together define a spiro-cyclopropyl or spiro-cyclobutyl ring~~, both optionally mono or di-substituted with R^{7a} wherein~~;

~~R^{7a} is C_1-C_6 alkyl, C_3-C_5cycloalkyl, or C_2-C_6 alkenyl, any of which is optionally substituted with halo; or R^{7a} is J~~.

47-48. (Cancelled)

49. (Currently amended) A compound according to claim 1, wherein J is a 3 to 8-membered saturated or unsaturated alkylene chain optionally containing one to two heteroatoms independently selected from: -O-, -S- or $-NR^{12}$-, wherein R^{12} is H, C_1-C_6 alkyl, ~~such as methyl,~~ or $-C(=O)C_1$-C_6 alkyl~~, such as acetyl~~.

50. (Original) A compound according to claim 49, wherein J is a 4 to 7-membered saturated or unsaturated, all carbon alkylene chain.

51. (Original) A compound according to claim 49, wherein J is saturated or mono-unsaturated.

52. (Original) A compound according to claim 49, wherein J is dimensioned to provide a macrocycle of 14 or 15 ring atoms.

53. (Withdrawn) A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier therefore.

54. (Withdrawn) A pharmaceutical composition according to claim 53, further comprising an additional HCV antiviral, selected from nucleoside analogue polymerase inhibitors, protease inhibitors, ribavirin and interferon.

55-57. (Cancelled)

58 (New) A compound according to claim 4 wherein Rq is methyl.

59. (New) A compound according to claim 9, wherein R^{16} is H or methyl.

60. (New) A compound according to claim 41, wherein R^2 is cyclopropyl.

61. (New) A compound according to claim 27, with the partial structure:



62. (New) A compound according to claim 27, with the partial structure



63. (New) A compound according to claim 62, wherein Rq is C_1-C_3 alkyl

64. (New) A compound according to claim 63, wherein Rq is methyl.

65. (New) A compound according to claim 27, wherein W is –O-.

66. (New) A compound according to claim 27, wherein the C_0-C_3 alkyl moiety of R^8 is a bond.

67. (New) A compound according to claim 27, wherein R^{16} is H or methyl.

68. (New) A compound according to claim 27, wherein R^2 is optionally substituted C_3-C_7cycloalkyl,

69. (New) A compound according to claim 68, wherein R^2 is cyclopropyl.

70. (New) A compound according to claim 27, wherein J is a 3 to 8-membered saturated or unsaturated alkylene chain optionally containing one to two heteroatoms independently selected from: -O-, -S- or -NR^{12}- , wherein R^{12} is H, or C_1-C_6 alkyl.

71 (New) A compound according to claim 70, wherein J is a 4 to 7-membered saturated or unsaturated, all carbon alkylene chain.

72. (New) A compound according to claim 70, wherein J is saturated or mono-unsaturated.

73. (New) A compound according to claim 70, wherein J is dimensioned to provide a macrocycle of 14 or 15 ring atoms.

74. (New) A compound according to claim 27 wherein

A is $C(=O)NHSO_2R^2$;

R^2 is C_0-C_3alkylcarbocyclyl;

Rz is H;

Rq is H;

W is -O-;

J is a single 4 to 7-membered mono-unsaturated alkylene chain that extends from the $R^7/R^{7'}$ cycloalkyl to G and forms a macrocycle;

G is -NRy-;

Ry is J;

R^{16} is C_1-C_6alkyl;

R^8 is heteroaryl, which is optionally mono, di, or tri substituted with R^9, wherein;

R^9 is C_1-C_6 alkyl, C_1-C_6alkoxy, or heteroaryl, the heteroaryl being optionally substituted with R^{10}; wherein R^{10} is C_1-C_6alkyl.

75. (New) A compound according to claim 27 wherein

R^2 is cyclopropyl;

Rz is H;

Rq is H;

W is -O-; and

J is a single mono-unsaturated alkylene chain that extends from the $R^7/R^{7'}$ cyclopropyl to G and forms a macrocycle dimensioned to provide a macrocycle of 14 or 15 ring atoms.

76. (New) A pharmaceutical composition comprising a compound as defined in claim 27 and a pharmaceutically acceptable carrier therefor.

77. (New) A pharmaceutical composition according to claim 27, further comprising an additional HCV antiviral, selected from nucleoside analogue polymerase inhibitors, protease inhibitors, ribavirin and interferon.

78. (New) A compound selected from the group consisting of:
(Z)-(1R,4R,6S,16R,18R)-14-*tert*-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diaza-tricyclo[14.3.0.0.^{4,6}]nonadec-7-ene-4-carboxylic acid ethyl ester;
(Z)-(1R,4R,6S,16R,18R)-14-tert-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diaza-tricyclo[14.3.0.0.^{4,6}]nonadec-7-ene-4-carboxylic acid;
17-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid ethyl ester;
17-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid;
Cyclopropanesulphonic acid [17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*octadec-7-ene-4-carbonyl]-amide;
17-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid ethyl ester;
17-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid ethyl ester;
Cyclopropanesulphonic acid [17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*octadec-7-ene-4-carbonyl]-amide;
[4-Cyclopropanesulphonylaminocarbonyl-17-(7-methoxy-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-en-13-yl]-carbamic acid tert.butyl ester;
Cyclopropanesulphonic acid[13-amino-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carbonyl]-amide trifluoroacetic acid salt;
Cyclopropanesulphonic acid {17-[2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carbonyl)-amide;

N-{4-[4-(4-Cyclopropanesulphonylaminocarbonyl-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6]octadec-7-en-17-yloxy)-7-methoxy-quinoli-2-yl]-thiazol-2-yl}-3,3dimethylbutyramide;

17-[2-(2-Isopropylamino-thiazol-4-yl)-7-methoxy-quionlin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid ethyl ester;

17-[2-(2-Isopropylamino-thiazol-4-yl)-7-methoxy-quionlin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid; and

Cyclopropanesulphonic acid {17-[2-(2-isopropylamino-thiazol-4-yl)-7-methoxy-quionlin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carbonyl}-amide.

79. (New) A pharmaceutical composition comprising a compound as defined in claim 78, and a pharmaceutically acceptable carrier therefor.

80. (New) A compound according to claim 1, wherein R^2 is optionally substituted phenyl.

81. (New) A compound according to claim 1, wherein A is $C(=O)OR^1$, wherein R^1 is methyl, ethyl, or tert-butyl.